Advisory Board on Cancer, Infertility and Pregnancy

Cancer Clinical Trial

— ABCIP  

Official title:

Advisory Board on Cancer, Infertility and Pregnancy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04904263
• Other study ID #: ABCIP
• Status: Recruiting
• Start date: May 22, 2021
• Est. completion date: May 22, 2024

Study information

• Verified date: May 2021
• Source: University Hospital, Gasthuisberg
• Contact: Frederic Amant, MD,PhD
• Phone: +32 16 344252
• Email: frederic.amant[@]uzleuven.be
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Advisory Board on Cancer, Infertility and Pregnancy provides a platform where physicians from all over the world can request recommendations regarding the medical care of pregnant women diagnosed with cancer or regarding fertility preservation. The platform will contain different national advisory boards, with their own coordinator and members, as well as an overarching international advisory board with an international coordinator and members from different national boards. To investigate the impact of this platform, a year after its launch, data regarding the incoming requests will be extracted from the website, as well as all recommendation letters.

Description:

The Advisory Board on Cancer, Infertility and Pregnancy (ABCIP)-platform will be a web-based platform where clinicians from all over the world can request advice from a group of experts on the field of Cancer and Pregnancy. The platform will contain different national advisory boards, with their own coordinator and members, as well as an overarching international advisory board with an international coordinator and members from different national boards. Clinicians can fill in a format (attached) requesting for advice, using only pseudonymized patient data after agreeing a disclaimer: All information filled in in the 'request advice' format needs to be regarded as anonymous or pseudonymous data. We recommend you to inform your patient and ask for approval when needed, based on the rules and regulations applicable in your country. The filled out request will be sent to the specific national board of their own country, and if no national board is available, to the overarching international board. . To investigate the impact of this platform, a year after its launch, data regarding the incoming requests will be extracted from the website, as well as all recommendation letters.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: May 22, 2024
• Est. primary completion date: May 22, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Pregnant women with a cancer diagnosis
• Women with a fertility related question after cancer diagnosis
• Postpartum cancer diagnosis
• Cancer treatment during pregnancy

Related Conditions & MeSH terms

• Cancer
• Fertility Preservation
• Infertility
• Pregnancy

Locations

Country	Name	City	State
Belgium	UZ Gasthuisberg, Katholieke Universiteit Leuven	Leuven

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Gasthuisberg	European Research Council, Kom Op Tegen Kanker

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The impact of an international advisory board on cancer in pregnancy	To investigate the impact of this platform, a year after its launch, data regarding the incoming requests will be extracted from the website, as well as all recommendation letters. All requesting physicians will be asked to complete a survey including their experiences with the ABCIP, to what amount they followed the given recommendations and the outcomes of mother (and child)	1 year

External Links

•   Link to the ABCIP platform